Bioscience investors have funded early stage research to identify innovative biological processes or screening techniques that accelerate exploration of a rapidly expanding biochemical "target space".

To go through the next stage of growth, these companies need to deliver data to customers in steadily increasing volumes and complexity, in a format that drug companies and research organizations can rapidly assimilate into their analysis and knowledge development platforms.

Company leadership has been built on deep understanding of the biological and chemical processes. But now, leadership recognizes the value in their proprietary process or technique can only be harnessed through the seamless transfer of data from the point of acquisition to the point of use.

Even though the biotech industry is in it's infancy, other industries have already solved similar problems of data organization, storage and transfer in standard formats, integrating automated equipment and processes, managing quality, and conforming to regulatory standards similar to 21CFR11.

Are some of these problems yours? >> Continue